| Literature DB >> 25359994 |
Joshua D Milner1, Tiphanie P Vogel2, Lisa Forbes3, Chi A Ma1, Asbjørg Stray-Pedersen4, Julie E Niemela5, Jonathan J Lyons1, Karin R Engelhardt6, Yu Zhang7, Nermina Topcagic8, Elisha D O Roberson9, Helen Matthews10, James W Verbsky11, Trivikram Dasu12, Alexander Vargas-Hernandez13, Nidhy Varghese14, Kenneth L McClain14, Lina B Karam14, Karen Nahmod3, George Makedonas3, Emily M Mace3, Hanne S Sorte15, Gøri Perminow16, V Koneti Rao10, Michael P O'Connell1, Susan Price10, Helen C Su7, Morgan Butrick10, Joshua McElwee17, Jason D Hughes17, Joseph Willet6, David Swan6, Yaobo Xu18, Mauro Santibanez-Koref18, Voytek Slowik19, Darrell L Dinwiddie20, Christina E Ciaccio21, Carol J Saunders22, Seth Septer19, Stephen F Kingsmore22, Andrew J White8, Andrew J Cant23, Sophie Hambleton23, Megan A Cooper24.
Abstract
Germline loss-of-function mutations in the transcription factor signal transducer and activator of transcription 3 (STAT3) cause immunodeficiency, whereas somatic gain-of-function mutations in STAT3 are associated with large granular lymphocytic leukemic, myelodysplastic syndrome, and aplastic anemia. Recently, germline mutations in STAT3 have also been associated with autoimmune disease. Here, we report on 13 individuals from 10 families with lymphoproliferation and early-onset solid-organ autoimmunity associated with 9 different germline heterozygous mutations in STAT3. Patients exhibited a variety of clinical features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity (lung, gastrointestinal, hepatic, and/or endocrine dysfunction), infections, and short stature. Functional analyses demonstrate that these mutations confer a gain-of-function in STAT3 leading to secondary defects in STAT5 and STAT1 phosphorylation and the regulatory T-cell compartment. Treatment targeting a cytokine pathway that signals through STAT3 led to clinical improvement in 1 patient, suggesting a potential therapeutic option for such patients. These results suggest that there is a broad range of autoimmunity caused by germline STAT3 gain-of-function mutations, and that hematologic autoimmunity is a major component of this newly described disorder. Some patients for this study were enrolled in a trial registered at www.clinicaltrials.gov as #NCT00001350.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25359994 PMCID: PMC4304103 DOI: 10.1182/blood-2014-09-602763
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113